Cardiac Resynchronization Therapy Market Trend, Share, Growth, Size Analysis, Forecast 2032

Cardiac Resynchronization Therapy Market: Industry Prospective

The global Cardiac Resynchronization Therapy market size accrued earnings worth approximately USD 4.26 Billion in 2023 and is predicted to gain revenue of about USD 6.56 Billion by 2032, is set to record a CAGR of nearly 4.9% over the period from 2024 to 2032.

Request Free Sample

Cardiac Resynchronization Therapy Market Overview

Cardiac resynchronization treatment was launched at the end of twentieth century. It has brought a paradigm shift in the medical treatment and has proved a boon for patients with systolic heart failure symptoms. The key objective of the cardiac resynchronization therapy is restoring of mechanical synchrony through electric activation of heart in a synchronized way. Clinical trials have demonstrated favorable outcomes when the patients exhibiting the heart failure symptoms are given combined cardiac resynchronization & medical treatment. Moreover, these combined treatments not only diminishes heart failure hospitalizations but also minimizes rate of mortality along with enhancing quality of life of patients. `

Request Free Sample

Cardiac Resynchronization Therapy Market Growth Dynamics

Cardiac resynchronization treatment has brought revolutionary changes in the patient care sector and this will boost the market growth over the upcoming years. With CRT or cardiac resynchronization therapy established as device treatment for heart failure patients, the cardiac resynchronization therapy industry is likely to gain traction over the forthcoming years. Apart from this, current know-how of implantation procedures, breakthroughs in device-based systems, and successful clinical trial outcomes has notably influenced the expansion of the cardiac resynchronization therapy business in recent years.

Furthermore, the therapy has proved to be an effective tool for treating patients with refractory heart failure symptoms, patients with serious left ventricle systolic dysfunctioning, and intraventricular conduction delay. CRT improves exercise tolerance and minimizes LV dilation, thereby proliferating market growth. According to studies conducted by NIH researchers, cardiac resynchronization treatment has resulted in reduction in proinflammatory and neurohormonal biomarkers. It also helps in enhancing heart pump proficiency and restoring ventricular contraction synchrony along with improving heart stole volume as well as LV contraction & ejection fraction. The main aim of the cardiac resynchronization treatment is maintaining interventricular & intraventricular synchrony. Apparently, introduction of novel cardiac resynchronization treatment systems along with growing trend of using wireless cardiac resynchronization therapy systems as well as adaptive optimization of CRT programming & multipoint pacing are predicted to influence the growth of cardiac resynchronization therapy market in the next decade.

Cardiac Resynchronization Therapy Market Report Scope

Cardiac Resynchronization Therapy Market Segmentation Analysis

The main divisions in the CRT market include Cardiac Resynchronization Therapy – Defibrillators (CRT-D), Wireless – Cardiac Resynchronization Therapy (Wireless-CRT), and Cardiac Resynchronization Therapy – Pacemakers (CRT-P). The selection of CRT implant is contingent upon several parameters like as age, gender, and others. The CRT-D segment held the largest market share in 2023.

Cardiac resynchronization treatment – defibrillator (CRT-D) employs an implantable cardioverter defibrillator (ICD) to enhance the synchronization of the heart's rhythm. This device employs three leads, with one connected to the right atrium and one connected to each of the ventricles.

Asia Pacific Market To Record Highest Growth Rate Over 2024-2032

The growth of the industry in Asia Pacific continent over the assessment period is due to surge in the heart disorders and improvement in the healthcare services in various countries of the region. Apart from this, favorable medical health insurance policies in the countries like Japan and India will further prompt the regional market trends.

Key players profiled in the report include

• Boston Scientific Corporation
• Abbott Laboratories
• Medico S.p.A.
• Medtronic
• MicroPort Scientific Corporation
• and BIOTRONIK

The global cardiac resynchronization therapy market is segmented as follows:

By Product Type

• Cardiac Resynchronization Therapy Defibrillators
• Cardiac Resynchronization Therapy Pacemakers

By End User

• Hospitals & Cardiac Centers
• Ambulatory Surgery Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa